Aug. 18 at 1:37 PM
$CGEM UBS raised its price target on Cullinan Oncology Inc. (NASDAQ:CGEM) to
$27 from
$24 while maintaining a Buy rating following positive Phase 3 trial results. UBS raised zipalertinib’s probability of success in first-line treatment to 85% from 40% based on the trial data. The firm projects
$500 million unadjusted peak sales potential for zipalertinib in first-line treatment and
$700 million combined first-line and second-line-plus unadjusted peak sales.
